Inhibikase Therapeutics, Inc. carries no debt; cash flow comfortably covers obligations.

Inhibikase Therapeutics, Inc.'s free cash flow has decreased 45.11% from $-19.15M last year to $-27.79M, signaling decreasing performance

Inhibikase Therapeutics, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Inhibikase Therapeutics, Inc.'s debt has decreased relative to shareholder equity from 0.00 last year to 0.00 today, signaling strengthened financials

Inhibikase Therapeutics, Inc. has negative EBITDA, making leverage ratio unreliable

Inhibikase Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Inhibikase Therapeutics, Inc. has insufficient data to evaluate this check.

Inhibikase Therapeutics, Inc.'s short-term assets of $180.11M exceed its short-term liabilities of $8.30M

Inhibikase Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Inhibikase Therapeutics, Inc.'s return on equity of -41.31%, is lower than 15.00%, indicating bad performance

Inhibikase Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Inhibikase Therapeutics, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Inhibikase Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Inhibikase Therapeutics, Inc. has negative free cash flow, indicating cash burn

Inhibikase Therapeutics, Inc.'s yearly earnings has decreased 75.36% since last year from $-27.52M to $-48.26M, signaling decreasing performance

Inhibikase Therapeutics, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -33.17% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Inhibikase Therapeutics, Inc.'s 3-year revenue CAGR of -100.00% is negative, indicating declining revenue over the past 3 years

Inhibikase Therapeutics, Inc. had revenue growth in 3.00 out of 5 years, indicating consistent revenue performance

Inhibikase Therapeutics, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Inhibikase Therapeutics, Inc. is overvalued relative to its fair value price of 1.49 based on Discounted Cash Flow model

Inhibikase Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Inhibikase Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Inhibikase Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Inhibikase Therapeutics, Inc. has insufficient data to evaluate this check.

Inhibikase Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Inhibikase Therapeutics, Inc. has a price-to-book ratio of 1.12x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Inhibikase Therapeutics, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue